secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2021-07-12T23:59:59+00:00
Accession:  0001628280-21-013733
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology appoints Dr. Ruffner as CMO and James Levine as CFO, with inducement options
--------------------------------------------------------------------------------

- Dr. Ruffner appointed CMO, receives $430k base salary, 45% target bonus, and option for 200,000 shares at $6.55.
- James Levine appointed CFO, receives $425k base salary, 45% target bonus, and option for 390,000 shares at $6.55.
- Options vest over 4 years: 25% at 12 months, then monthly; granted as inducement under Nasdaq Rule 5635(c)(4).
- Ruffner brings 25+ years oncology drug development; Levine has 20+ years biotech investment banking and corporate finance.
- Levine's employment agreement includes severance: 12 months salary if terminated without cause or for good reason, plus accelerated vesting upon change of control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000162828021013733/0001628280-21-013733-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000162828021013733/crdf-20210706.htm
  HTML page:      https://secwatch.observer/filing/0001628280-21-013733

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer